United States Drug Patent 9,072,697: Claim Scope, Expiration, Gocovri Coverage, and Generic Risk

U.S. Patent No. 9,072,697 protects once-daily administration of extended-release amantadine for Parkinson’s disease, particularly dyskinesia associated with levodopa therapy. The patent is method-of-treatment protection, not a stand-alone composition patent. Its core limitations are the amantadine dose, extended-release proportion, dissolution profile, Parkinson’s indication, and once-daily oral administration.

The patent issued July 7, 2015, to Adamas Pharmaceuticals, Inc. Its principal commercial relevance is Gocovri, an extended-release amantadine hydrochloride capsule approved by the FDA for dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.[1][2]

What does U.S. Patent 9,072,697 protect?

The patent protects a defined clinical-use protocol involving:

Limitation	Scope
Active drug	Amantadine or a pharmaceutically acceptable salt
Administration	Oral, once daily
Patient	Human subject with Parkinson’s disease
Dose	200 to 500 mg daily; dependent claims narrow this to 300 to 500 mg
Release profile	At least 50% of the amantadine in extended-release form
Dissolution	Defined USP Type 2 paddle profile
Therapeutic use	Parkinson’s disease, including dyskinesia and levodopa-induced dyskinesia
Combination therapy	Optional levodopa/carbidopa administration
Pharmacokinetics	A 2-to-16-hour delay in amantadine Tmax compared with immediate-release amantadine
Delivery technology	May include an osmotic delivery device

The claims require a combination of structural, analytical, pharmacokinetic, dosing, and treatment limitations. A product does not infringe merely because it contains extended-release amantadine. The accused product and use must satisfy the limitations of at least one asserted claim.

How are claims 1 through 3 different?

Claims 1 through 3 are independent method claims with overlapping scope.

Claim 1

Claim 1 requires a composition containing amantadine and at least one excipient, with at least 50% of the drug in extended-release form. The complete composition must meet all three dissolution windows:

35% to 55% dissolved at two hours;
60% to 80% dissolved at four hours; and
more than 90% dissolved at eight hours.

The claim applies to a daily dose of 200 to 500 mg.

Claim 2

Claim 2 is materially similar to claim 1 but states that the extended-release form of the composition has the required dissolution profile. That wording may create a claim-construction dispute over whether the dissolution test applies to the entire dosage form or only to the extended-release fraction.

Claim 3

Claim 3 omits the two-hour dissolution requirement. It requires only:

60% to 80% dissolution at four hours; and
more than 90% dissolution at eight hours.

This makes claim 3 potentially broader than claims 1 and 2 with respect to early release. A product outside the 35% to 55% two-hour window could still fall within claim 3 if it meets the four-hour and eight-hour limitations.

What dependent claims add to the patent scope?

Claim	Added limitation
4	Daily dose of 300 to 500 mg
5	At least 75% of drug in extended-release form
6	At least 90% of drug in extended-release form
7	At least some drug may be immediate-release
8	Dose is therapeutically effective for Parkinson’s disease
9	Patient suffers from dyskinesia
10	Treatment reduces dyskinesia frequency or severity
11	Dyskinesia is levodopa-induced
12	Concurrent pharmaceutically effective levodopa/carbidopa
13	Amantadine Tmax shifts by two to 16 hours
14	Extended-release form uses an osmotic device
15	Bioavailability is maintained
16	Therapeutically effective once-daily dosing begins at treatment onset

Claims 5 and 6 increase the extended-release requirement but do not necessarily narrow the dissolution profile. Claim 7 confirms that a dosage form can include both immediate-release and extended-release amantadine. That limitation is important because a product need not be entirely extended release to fall within the patent.

Claim 14 is narrower and technically specific. It reaches osmotic delivery systems, including dosage forms that use osmotic pressure to control drug release. It does not convert the entire patent into an osmotic-device patent because the independent claims do not require that technology.

What formulations are protected by U.S. Patent 9,072,697?

The patent covers dosage forms with at least 50% extended-release amantadine and may cover formulations containing both immediate-release and extended-release fractions. The claims do not require a particular capsule, tablet, polymer, coating, membrane, excipient, or manufacturing process.

The claimed formulation must satisfy the specified dissolution test:

USP Type 2 paddle apparatus;
50 rpm;
water as the dissolution medium;
37 ± 0.5°C;
measurement at two, four, and eight hours.

The dissolution limitations are central claim boundaries. A formulation with the wrong release curve may avoid claims 1 through 3 even if it uses the same active ingredient and is administered once daily.

The patent does not claim every extended-release amantadine formulation. It claims a treatment method using a formulation with specified release behavior. Separate formulation patents may protect the dosage form, manufacturing method, coating system, or osmotic mechanism independently.

Does the patent cover Gocovri?

Gocovri is an extended-release amantadine hydrochloride capsule approved for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medication.[2]

The FDA-approved Gocovri regimen is generally:

137 mg once daily at bedtime for initial treatment; and
274 mg once daily at bedtime after titration.

The patent’s claims recite 200 to 500 mg of drug per day. Because amantadine hydrochloride contains less amantadine base by weight than the salt quantity, infringement analysis must address whether the claimed dose refers to amantadine free base, amantadine hydrochloride, or the drug quantity as used in the relevant patent specification and regulatory records.

This distinction is commercially important. A 274 mg amantadine hydrochloride capsule does not necessarily contain 274 mg of amantadine base. Claim construction and product-specific assay data would determine whether the approved dose falls within the patent’s stated dose range.

Gocovri’s pharmacology and dosing are consistent with the patent’s claimed objectives: extended exposure, once-daily administration, and reduced peak-to-trough fluctuation compared with immediate-release amantadine.[2]

When does U.S. Patent 9,072,697 expire?

The patent’s nominal term is generally calculated from the earliest effective nonprovisional filing date under the 20-year patent-term framework, subject to patent-term adjustment and any applicable terminal disclaimer.[3]

Public patent records identify the patent as having a 2029 expiration period. The controlling date is the expiration date shown in the USPTO patent record after accounting for patent-term adjustment, not the issue date.[1][4]

Event	Date or period
Patent issued	July 7, 2015
Expected patent-term horizon	2029
FDA approval of Gocovri	August 24, 2017
Statutory patent extension	Must be confirmed from the current USPTO/FDA records
Regulatory exclusivity	Separate from patent term and does not extend the patent automatically

FDA approval does not itself extend a drug patent. Any patent-term extension under 35 U.S.C. § 156 would require a specific regulatory determination.[3]

What is the FDA Orange Book status of patent 9,072,697?

The FDA Orange Book lists patent information submitted by an NDA holder for approved drug products. Orange Book listing does not mean that the patent covers every use of the active ingredient. It means the NDA holder has submitted the patent for the approved product and its labeling or method of use under FDA listing procedures.[5]

For Gocovri, patent 9,072,697 has been associated with the product’s patent estate. Other Gocovri-related patents have also been listed over time, including patents directed to extended-release amantadine formulations and methods of treating dyskinesia.[5]

The practical effect is that an ANDA applicant seeking approval of a therapeutically equivalent generic may need to address the listed patents through:

Paragraph I certification, if the patent information is no longer relevant;
Paragraph II certification, if the patent has expired;
Paragraph III certification, accepting approval after patent expiration; or
Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed.

A Paragraph IV notice can trigger patent litigation and a potential 30-month FDA approval stay under the Hatch-Waxman Act.[6]

Which companies are challenging the Gocovri patent estate?

The principal commercial challenge would come from ANDA applicants seeking approval of generic extended-release amantadine capsules. Patent litigation may involve the NDA holder, its successor, licensees, or a generic applicant that submitted a Paragraph IV certification.

Adamas Pharmaceuticals was acquired by Supernus Pharmaceuticals in 2021. Supernus became the commercial owner of the Gocovri business and related intellectual-property interests.[7]

The key legal issue for a generic applicant is whether its proposed product meets each limitation of the asserted claims. A generic could pursue several noninfringement positions:

The product does not meet the claimed dissolution intervals.
The product contains less than the required proportion of extended-release drug.
The proposed label does not induce treatment of the claimed Parkinson’s population.
The approved dose falls outside the claimed 200-to-500 mg range.
The product uses a different release mechanism and does not satisfy the osmotic-device limitation in claim 14.
The product’s pharmacokinetics do not produce the claimed Tmax shift.

An invalidity challenge could focus on obviousness, anticipation, enablement, written description, indefiniteness, or claim construction. The dissolution profile and dose-range limitations are likely to become central expert issues.

How strong is the patent estate for Gocovri?

The patent estate is stronger than a single-patent analysis suggests because multiple protection layers may apply:

Protection layer	Business purpose
Method claims	Protect once-daily Parkinson’s treatment
Dyskinesia claims	Target the principal approved indication
Formulation claims	Protect extended-release dosage forms
Dissolution claims	Define release behavior analytically
Osmotic-device claims	Protect a specific delivery platform
FDA Orange Book listings	Create Hatch-Waxman litigation exposure
Regulatory exclusivity	Delay certain competing approvals for a limited period

Patent 9,072,697 has meaningful value because it combines a commercially relevant indication with a defined extended-release profile. Its weaknesses are also identifiable. The claims depend heavily on measurable parameters that can be designed around, tested differently, or contested through claim construction.

The use claims may also be vulnerable if a generic applicant obtains approval with a label that omits the patented indication or does not encourage the claimed dosing regimen. That strategy is fact-specific and does not eliminate liability if physicians, pharmacists, or marketing materials support induced infringement.

What patent litigation affects extended-release amantadine?

Patent litigation involving Gocovri is likely to center on Hatch-Waxman procedures, ANDA filings, and asserted Orange Book patents. The relevant litigation questions are:

Which patents were listed for the specific Gocovri strength and indication?
Which generic applicants submitted Paragraph IV certifications?
When were notices served?
Was a 30-month stay triggered?
Did the parties settle?
Does the settlement impose a licensed entry date?
Were patent claims dismissed, invalidated, or upheld?

A settlement can establish a confidential or public generic-entry date without invalidating the patent. A court judgment can also address only certain claims or products. Patent expiration, settlement entry dates, and FDA approval dates must therefore be tracked separately.

What generic launch scenarios exist?

Launch after patent expiration

This is the lowest-risk scenario. The generic applicant accepts a Paragraph III certification or waits for expiration of the relevant listed patents.

Launch after successful Paragraph IV litigation

The generic may launch if the asserted claims are held invalid, unenforceable, or not infringed, subject to appeal and other listed patents.

Launch under a settlement license

The parties may agree to an authorized or licensed entry date before the latest patent expiration. The commercial launch date depends on settlement terms, regulatory approval, manufacturing readiness, and any exclusivity held by the first Paragraph IV filer.

Carved-out labeling

A generic may omit a patented indication or method from its label under a section viii statement. This approach is less effective when the product’s remaining label, dosing instructions, or marketing conduct still encourages the patented use.

Is there biosimilar risk for Gocovri?

No. Gocovri contains amantadine hydrochloride, a small-molecule active ingredient. Competition would proceed through the ANDA pathway for a generic drug, not the biosimilar pathway under the Public Health Service Act.

The principal barriers are formulation equivalence, dissolution matching, bioequivalence, patent certifications, and manufacturing scale. FDA approval would require the generic product to meet the applicable pharmaceutical-equivalence and bioequivalence standards.[6]

How does Gocovri compare with other amantadine products?

Product type	Release	Typical use	Patent risk
Immediate-release amantadine	Immediate release	Parkinson’s disease and other approved uses	Lower exposure to this patent
Gocovri	Extended release, once daily	Dyskinesia in Parkinson’s patients receiving levodopa	Direct exposure to the patent estate
Other extended-release amantadine	Extended release	Parkinson’s disease or drug-induced extrapyramidal reactions, depending on label	Product-specific infringement analysis
Generic extended-release amantadine	Extended release	Depends on approved label	Orange Book and Paragraph IV risk

A competing extended-release product can avoid infringement if it does not meet the claimed dissolution profile, dose range, or method-of-use limitations. It may still face other formulation or method patents.

What are the manufacturing and IP barriers?

The key technical barriers are:

reproducible multi-hour release;
control of early and late dissolution;
maintenance of exposure over a 24-hour dosing interval;
stability of amantadine hydrochloride in the dosage form;
scalable coating, membrane, matrix, or osmotic processing;
bioequivalence against the reference product;
consistency across commercial batches.

An osmotic system can create additional manufacturing barriers because membrane permeability, delivery orifice dimensions, osmotic agents, and core composition must be tightly controlled. Those features may be protected by separate formulation patents even when a product avoids claim 14 of patent 9,072,697.

What is the commercial exposure from patent 9,072,697?

Gocovri revenue is exposed to generic entry because the product has no biologic exclusivity barrier and uses a small-molecule active ingredient with a long history of generic availability in immediate-release form.

The commercial exposure is concentrated in the extended-release product and its approved dyskinesia indication. Generic entry could cause:

rapid price erosion;
substitution from branded Gocovri;
payer-mandated generic conversion;
loss of branded market share;
reduced value of licenses and co-promotion arrangements.

The degree of exposure depends on whether a generic can obtain approval for the same strength, demonstrate bioequivalence, avoid the listed patents, and market the product without inducing the patented use.

Key Takeaways

U.S. Patent 9,072,697 protects methods of once-daily oral administration of extended-release amantadine for Parkinson’s disease.
The principal claim limitations are the 200-to-500 mg daily dose, at least 50% extended-release drug, and defined dissolution profile.
Dependent claims reach dyskinesia, levodopa-induced dyskinesia, levodopa/carbidopa combination therapy, delayed Tmax, maintained bioavailability, and osmotic delivery.
The patent is method-of-treatment protection, not a universal patent on amantadine or every extended-release amantadine formulation.
Gocovri is the principal commercial product associated with the patent estate.
The patent has a 2029 expiration horizon, subject to the official USPTO term calculation and any adjustment.
Generic applicants face Orange Book certification and Paragraph IV litigation risk.
Biosimilar competition is irrelevant because amantadine is a small-molecule drug.
The most viable design-around strategies involve dissolution profile, dose, release fraction, labeling, and delivery technology.
The broader Gocovri patent estate, rather than patent 9,072,697 alone, determines practical generic-entry risk.

FAQs

Does patent 9,072,697 cover immediate-release amantadine?

No. The claims require that at least 50% of the drug be in extended-release form. Immediate-release amantadine alone would not satisfy the independent claims.

Can a generic use the same amantadine dose but a different dissolution profile?

Potentially. A product outside the claimed dissolution ranges may avoid claims 1 through 3, but other listed formulation or method patents could still apply.

Does claim 14 cover every osmotic amantadine product?

No. Claim 14 requires an extended-release form that uses an osmotic device. The product must also satisfy all limitations incorporated from the underlying independent claim.

Can a generic sell extended-release amantadine for a non-patented indication?

Possibly, if its label and commercial conduct do not induce the patented Parkinson’s or dyskinesia use. The analysis depends on the final FDA label and marketing behavior.

Is the 274 mg Gocovri dose automatically within the patent’s 200-to-500 mg range?

No. The answer depends on how the claim defines the drug quantity and whether the relevant amount is measured as amantadine base or amantadine hydrochloride. The product’s labeled strength and the patent’s construction must be compared.

References

United States Patent and Trademark Office. (2015). U.S. Patent No. 9,072,697, Methods of treating Parkinson’s disease with extended release amantadine.
U.S. Food and Drug Administration. (2023). Gocovri (amantadine) extended-release capsules: Prescribing information. Adamas Pharma, LLC.
35 U.S.C. §§ 154, 156.
United States Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 9,072,697.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. §§ 355(j), 271(e).
Supernus Pharmaceuticals, Inc. (2021). Acquisition of Adamas Pharmaceuticals, Inc. and GOCOVRI commercial operations.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2588296	⤷ Start Trial
European Patent Office	1845968	⤷ Start Trial
European Patent Office	2623099	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,072,697

Summary for Patent: 9,072,697